中文
EN
News Center
News Center
Viwit 2025 Annual Shareholders’ Meeting Successfully Concluded | Focus on Innovation, Steady Progress
Author：
VIWIT
Release Time：
2026-06-06
On June 6, 2026, Viwit’s 2025 Annual Shareholders’ Meeting was held. All shareholders, directors, and management gathered for efficient discussions on corporate strategy, operations, and governance, completing all agenda items.
The meeting was chaired by Board Secretary Ms. Yanping Xing. Dr. Keene Wei, Chairman and President, delivered the “2025 Annual Work Report,” systematically outlining the company’s current status, strategic planning, and related work deployments. The report reviewed Viwit’s development journey: years of dedication to industrial depth, steady construction of a full-industry-chain layout, and the chain-upgraded innovation development path covering multiple therapeutic areas with a multi-therapeutic pharmaceutical product pipeline.
Regarding internal development, the report covered five dimensions – strategic positioning, talent building, technological innovation, refined operations, and staying true to the corporate mission – highlighting commercial achievements such as the mass production, sales, and export of self-developed products VivaQuit and VivaHearts. Finally, grounded in the corporate mission, the report outlined the future direction: focusing on first-in-class new drug R&D and advancing IPO filing according to the established timeline.
After the report, shareholders asked questions and offered suggestions on operations, development plans, and management. One shareholder raised the topic of rapid AI development and the company’s perspective on AI. Dr. Wei responded that AI is essentially a tool. Those who can best utilize it will become stronger. Viwit has already introduced AI assistance in drug design, and AI has also been integrated into daily office and R&D processes. Another shareholder inquired about intellectual property protection given the high risk of infringement in the pharmaceutical industry. Board Secretary Ms. Xing noted that the company places high importance on IP, starting patent protection from the compound stage for innovative drug discoveries and extending to process technologies, while also making global patent arrangements via PCT routes in major pharmaceutical markets, laying a solid foundation for international competition.
Subsequently, the shareholders reviewed and approved eight important proposals, including the “2025 Board of Directors Work Report” and the “2025 Supervisory Committee Work Report.”
At the conclusion, Executive Vice President Mr. Xinhai Guo delivered a closing speech. He thanked all shareholders for their long-term trust and support. He noted that the meeting not only completed the planned review procedures but, more importantly, through open and in-depth dialogue, further clarified the direction for improvement and reached a development consensus. He sincerely hoped shareholders would continue to support Viwit, offer valuable suggestions, and together help the company navigate the challenging yet opportunity-rich pharmaceutical industry with steady and far-reaching progress.
The meeting ended in a warm and pragmatic atmosphere. Looking ahead, Viwit will continue to uphold its core values of integrity, dedication, responsibility, and initiative. Driven by innovation and rooted in quality, Viwit will focus on new drug R&D, accelerate global clinical development, seize opportunities amid change, and forge ahead through challenges, contributing Viwit’s strength to the protection of human health.